What happened
FDA’s February 19–27, 2026 inspection of Reliance Life Sciences’ Navi Mumbai drug facility identified significant CGMP violations involving laboratory data, sterile manufacturing, and quality oversight. FDA found environmental monitoring and other microbiology samples recorded as collected and incubated even though plates were absent and analysts confirmed the samples were not collected. LIMS calculations omitted required dilution factors, while electronic integrity-testing files lacked unique names and were overwritten; testing was also not performed for one plant. FDA said these deficiencies created a risk of underreported microbial findings and unreliable batch-release evidence. In aseptic operations, investigators observed operators blocking unidirectional airflow over critical locations and not discarding potentially compromised vials. FDA also observed deteriorated or damaged manufacturing areas or components, excess sealant near HEPA filters, nonsterile wipes used for cleaning, and standing water and staining near pipelines. FDA deemed the firm’s responses insufficient, citing incomplete remediation detail, traceability, oversight, and timelines. The company agreed to recall all sterile drugs and suspend U.S.-market production; FDA later placed its drugs on Import Alert 66-40.
Why it matters
From a GMP and pharmaceutical manufacturing perspective, inaccurate or overwritten microbiology and integrity-testing records may prevent the quality unit from reliably assessing batch conformity, investigating deviations, and identifying contamination risks. Missing dilution factors may lead to understated microbial results. Airflow obstruction, deficient interventions, damaged or poorly maintained aseptic equipment, unsuitable cleaning materials, and standing water may weaken contamination control and sterility assurance. FDA’s requested retrospective testing, contamination-risk assessments, CAPA, independent review, and quality-unit remediation reflect the systemic scope of the concerns.
Key topics: Microbiology samples recorded but not collected and omitted LIMS dilution factors, Overwritten integrity-testing records and incomplete leak-test traceability, First-air obstruction and deficient aseptic equipment cleaning and maintenance